Citryll has dosed the first patient in the Phase IIa Citylights clinical trial of the monoclonal antibody, CIT-013, for moderate-to-severe hidradenitis suppurativa (HS), a chronic autoimmune disease.

The MarketWatch News Department was not involved in the creation of this content. SEATTLE, March 10, 2026 /PRNewswire/ -- CounterX Therapeutics, a biotechnology company focused on developing novel ...

(Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 ...

The U.S. Food and Drug Administration (FDA) today released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)(1) , a sweeping guidance that codifies multiple regulatory ...

Comparing Denmark to the U.S. is like comparing an apple to a wide assortment of fruits. Denmark's health outcomes are driven by its social welfare system, including paid parental leave, affordable ...

Title: 79594 - Rademikibart monotherapy in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD): A 1-year, phase III, randomized, double-blinded, placebo-controlled trial ...

With the mAb therapeutic market expected to reach $300 billion by 2025, their role in transforming the therapeutic landscape is undeniable. | Ebooks ...

The NDAs cover all approved indications of toripalimab in Mainland China.

So welcome to our second IR went in 2026, focusing this time on the Phase III ALLEGORY results for Gazyva in SLE, which just got presented last Friday at SLEuro. Today's call is scheduled for 60 ...

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, ...

Genmab is focused on the development of monoclonal antibody and bispecific antibody therapies in oncology indications. The company's best-known drug, Darzalex (or daratumumab), was developed in ...